Enanta Pharmaceuticals, Inc.
(ENTA)
Add Watchlist
12.13 USD -0.04
Closed: 17 May, 3:55 pm
Symbol ENTA
Market Cap 256.9M
Price 12.13
Open 13.02
52-wk High 28.25
50 Day Avg 14.57
Earnings Announcement 2024-08-05
Website https://www.enanta.com
Name Enanta Pharmaceuticals, Inc.
Shares Outstanding 21,179,400
Change % -7.121%
Low 12.06
52-wk Low 8.08
200 Day Avg 12.47
Last Dividend 0.00
Exchange NASDAQ
Volume 248,761
Previous Close 13.06
High 13.02
EPS -6.25
PE -1.94
Avg Volume 196,988
CUSIP 29251M106
Enanta Pharmaceuticals, Inc. Outlook
Description Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
Currency USD
ISIN US29251M1062
Industry Biotechnology
Changes -0.93
CUSIP 29251M106
Range 8.08 - 28.25
Beta 0.54
CIK 0001177648

Enanta Pharmaceuticals, Inc. News

07-May-2024 7:00 AM

Enanta Pharmaceuticals to Participate at the JMP Securities Life Sciences Conference

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, and Tara L. Kieffer, Ph.D., Chief Product Strategy Officer, will participate in a fireside chat at the JMP Securities Life Sciences Conference on May 14, 2024 at 10:00 a.m. ET in New York, NY. A live webcast of the ev.

06-May-2024 8:34 PM

Enanta Pharmaceuticals, Inc. (ENTA) Q2 2024 Earnings Call Transcript

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA ) Q2 2024 Earnings Conference Call May 6, 2024 4:30 PM ET Company Participants Jennifer Viera - Investor Relations Jay Luly - President and Chief Executive Officer Paul Mellett - Chief Financial Officer Scott Rottinghaus - Chief Medical Officer Tara Kieffer - Chief Product Strategy Officer Conference Call Participants Eric Joseph - JPMorgan Roy Buchanan - Citizens JMP Nik Gasic - Leerink Partners Jay Olson - Oppenheimer Operator Good afternoon and welcome to Enanta Pharmaceuticals' Fiscal Second Quarter Financial Results Conference Call. At this time, all participants are on a listen-only mode.

06-May-2024 6:11 PM

Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Tops Revenue Estimates

Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.47 per share versus the Zacks Consensus Estimate of a loss of $1.26. This compares to loss of $1.79 per share a year ago.

06-May-2024 4:01 PM

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Webcast and Conference Call Today at 4:30 p.m. ET

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today reported financial results for its fiscal second quarter ended March 31, 2024. “At Enanta, we are committed to advancing the first antiviral treatment for RSV, and more broadly developing important medicines in virology and immunology. Our commitment is highlighted by our goal to deliver mu.

30-Apr-2024 7:10 AM

Enanta Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that effective April 29, 2024, the Compensation Committee of Enanta Pharmaceuticals' Board of Directors granted employment inducement awards to Matthew P. Kowalsky, Enanta's new Chief Legal Officer, consisting of a non-qualified stock option to purchase 150,000 shares of its commo.

30-Apr-2024 7:00 AM

Enanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal Officer

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the appointment of Matthew P. Kowalsky, J.D., as Chief Legal Officer. In this role, he will lead all legal and compliance activities for Enanta, as well as provide strategic guidance and corporate governance oversight. “I'm pleased to welcome Matt to Enanta. The breadth of his leg.

29-Apr-2024 7:00 AM

Enanta Pharmaceuticals to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2024

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that it plans to report its financial results for its fiscal second quarter ended March 31, 2024, after the U.S. market closes on May 6, 2024. Enanta management will host a conference call at 4:30 p.m. ET to discuss these results and provide an update on Enanta's business, includ.

17-Apr-2024 7:00 AM

Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for indications in virology and immunology, today announced that data from the company's SPRINT (SARS-Cov-2 PRotease INhibitor Treatment) study of EDP-235 has been accepted for a poster presentation at ESCMID Global 2024 (formerly ECCMID) being held April 27–30 in Barcelona, Spain. The poster presentation includes primary and post-hoc a.

06-Mar-2024 7:00 AM

Enanta Pharmaceuticals to Participate at Leerink Partners Global Biopharma Conference

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for indications in virology and immunology, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, and Tara L. Kieffer, Ph.D., Chief Product Strategy Officer, will participate in a fireside chat at Leerink Partners Global Biopharma Conference on March 13, 2024 at 10:40 a.m. ET in Miami, FL. A live webcast of th.

07-Feb-2024 10:04 PM

Enanta Pharmaceuticals, Inc. (ENTA) Q1 2024 Earnings Call Transcript

Enanta Pharmaceuticals, Inc. (ENTA) Q1 2024 Earnings Call Transcript

07-Feb-2024 6:11 PM

Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Lags Revenue Estimates

Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.58 per share versus the Zacks Consensus Estimate of a loss of $1.18. This compares to loss of $1.39 per share a year ago.